Castleman Disease Treatment Market Regulatory Framework and Orphan...

added blog Health

2026-07-01 11:23:04 -

Castleman Disease Treatment Market Regulatory Framework and Orphan Drug Incentives

The regulatory landscape for Castleman disease treatment has evolved significantly to accommodate rare disease drug development, with specialized pathways and incentives that recognize the challenges of conducting traditional large-scale clinical trials in small patient populations. The U.S. Food and Drug Administration granted siltuximab orphan drug designation in 2007 and approved it for iMCD...

0 Comments 0 Shares 14 Views 0 Reviews